These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34743917)

  • 21. The Topography of Striatal Dopamine and Symptoms in Psychosis: An Integrative Positron Emission Tomography and Magnetic Resonance Imaging Study.
    McCutcheon RA; Jauhar S; Pepper F; Nour MM; Rogdaki M; Veronese M; Turkheimer FE; Egerton A; McGuire P; Mehta MM; Howes OD
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2020 Nov; 5(11):1040-1051. PubMed ID: 32653578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study.
    Howes OD; Bose SK; Turkheimer F; Valli I; Egerton A; Valmaggia LR; Murray RM; McGuire P
    Am J Psychiatry; 2011 Dec; 168(12):1311-7. PubMed ID: 21768612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1165-78. PubMed ID: 21087552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.
    Demjaha A; Murray RM; McGuire PK; Kapur S; Howes OD
    Am J Psychiatry; 2012 Nov; 169(11):1203-10. PubMed ID: 23034655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relation between dopamine D
    Wulff S; Nielsen MØ; Rostrup E; Svarer C; Jensen LT; Pinborg L; Glenthøj BY
    Psychol Med; 2020 Jan; 50(2):220-228. PubMed ID: 30642415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebral blood flow in striatum is increased by partial dopamine agonism in initially antipsychotic-naïve patients with psychosis.
    Bojesen KB; Glenthøj BY; Sigvard AK; Tangmose K; Raghava JM; Ebdrup BH; Rostrup E
    Psychol Med; 2023 Feb; 53(14):1-11. PubMed ID: 36754993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study.
    Rogdaki M; Devroye C; Ciampoli M; Veronese M; Ashok AH; McCutcheon RA; Jauhar S; Bonoldi I; Gudbrandsen M; Daly E; van Amelsvoort T; Van Den Bree M; Owen MJ; Turkheimer F; Papaleo F; Howes OD
    Mol Psychiatry; 2023 May; 28(5):1995-2006. PubMed ID: 33981004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia.
    Kubota M; Nagashima T; Takano H; Kodaka F; Fujiwara H; Takahata K; Moriguchi S; Kimura Y; Higuchi M; Okubo Y; Takahashi H; Ito H; Suhara T
    Int J Neuropsychopharmacol; 2017 Nov; 20(11):928-935. PubMed ID: 29016872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
    Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
    Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.
    Conway CR; Chibnall JT; Cumming P; Mintun MA; Gebara MA; Perantie DC; Price JL; Cornell ME; McConathy JE; Gangwani S; Sheline YI
    Psychiatry Res; 2014 Mar; 221(3):231-9. PubMed ID: 24468015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical response to treatment with a partial dopamine agonist is related to changes in reward processing.
    Tangmose K; Rostrup E; Bojesen KB; Sigvard A; Glenthøj BY; Nielsen MØ
    Psychiatry Res; 2023 Aug; 326():115308. PubMed ID: 37399765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms.
    Avram M; Brandl F; Cabello J; Leucht C; Scherr M; Mustafa M; Leucht S; Ziegler S; Sorg C
    Brain; 2019 Jun; 142(6):1813-1826. PubMed ID: 31135051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.
    Fusar-Poli P; Meyer-Lindenberg A
    Schizophr Bull; 2013 Jan; 39(1):33-42. PubMed ID: 22282454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.
    Fervaha G; Caravaggio F; Mamo DC; Mulsant BH; Pollock BG; Nakajima S; Gerretsen P; Rajji TK; Mar W; Iwata Y; Plitman E; Chung JK; Remington G; Graff-Guerrero A
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3803-3813. PubMed ID: 27557949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated striatal dopamine function linked to prodromal signs of schizophrenia.
    Howes OD; Montgomery AJ; Asselin MC; Murray RM; Valli I; Tabraham P; Bramon-Bosch E; Valmaggia L; Johns L; Broome M; McGuire PK; Grasby PM
    Arch Gen Psychiatry; 2009 Jan; 66(1):13-20. PubMed ID: 19124684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [
    Kim S; Jung WH; Howes OD; Veronese M; Turkheimer FE; Lee YS; Lee JS; Kim E; Kwon JS
    Psychol Med; 2019 Nov; 49(15):2533-2542. PubMed ID: 30460891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].
    Simon N; Azorin JM
    Encephale; 2018 Dec; 44(6):558-564. PubMed ID: 30466778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.